Holen Sie sich die Stockscreener-App
4.27
2.89%
0.12
Handel nachbörslich:
4.32
0.05
+1.17%
Schlusskurs vom Vortag:
$4.15
Offen:
$4.18
24-Stunden-Volumen:
3.80M
Relative Volume:
2.85
Marktkapitalisierung:
$1.66B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
169.44
EPS:
0.0252
Netto-Cashflow:
$64.06M
1W Leistung:
-12.68%
1M Leistung:
-38.21%
6M Leistung:
-42.91%
1J Leistung:
-18.36%
1-Tages-Spanne:
$4.16
$4.39
1-Wochen-Bereich:
$4.09
$4.95
52-Wochen-Spanne:
$4.09
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GDRX | 4.27 | 1.66B | 775.09M | -58.68M | 64.06M | 0.0252 |
| VEEV | 213.68 | 34.73B | 2.57B | 615.26M | 996.76M | 3.32 |
| SOLV | 67.12 | 11.43B | 8.25B | 404.00M | 1.52B | 0.00 |
| DOCS | 52.21 | 9.58B | 493.63M | 160.55M | 162.20M | 0.55 |
| HQY | 102.40 | 8.82B | 1.10B | 105.67M | -197.98M | 0.1475 |
| TEM | 54.06 | 8.51B | 640.44M | -743.28M | -206.93M | 0.00 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx (NASDAQ:GDRX) Sees Strong Trading VolumeHere's Why - MarketBeat
GoodRx (NASDAQ:GDRX) Shares Down 7.5%Here's Why - MarketBeat
Why GoodRx Holdings Stock Was Sinking This Week - AOL
AMERIPRISE FINANCIAL INC's Strategic Reduction in GoodRx Holdings Inc - GuruFocus.com
Rubric Capital Management LP's Strategic Acquisition in GoodRx H - GuruFocus.com
GoodRx stock hits 52-week low at $4.66 amid market challenges - Investing.com India
Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm - PR Newswire
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Barclays Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Reviewing TELUS International (Cda) (NYSE:TIXT) & GoodRx (NASDAQ:GDRX) - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Why GoodRx Holdings (GDRX) Stock is Moving Today - GuruFocus.com
Why GoodRx Holdings Stock Was Sinking This Week - The Motley Fool
GoodRx Holdings Inc (GDRX) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
GoodRx Holdings Inc (GDRX) Q3 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
GoodRx Holdings Inc (GDRX) Q3 2024 Earnings Call Highlights: Strong Financial Performance ... By GuruFocus - Investing.com Canada
GoodRx Holdings Reports Strong Q3 2024 Performance - TipRanks
GoodRx (GDRX) Q3 2024 Earnings Call Transcript - Yahoo Finance
GoodRx (NASDAQ:GDRX) Shares Down 13.9%Here's What Happened - MarketBeat
GoodRx Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GoodRx Reports Third Quarter 2024 Results - BioSpace
GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
GoodRx Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 - Marketscreener.com
GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates - Yahoo Finance
GoodRx Q3 revenue misses estimates, lowers full-year outlook By Investing.com - Investing.com Canada
GoodRx Q3 revenue misses estimates, lowers full-year outlook - Investing.com
GoodRx Holdings, Inc. (GDRX) Misses Q3 EPS by 1c ; Offers Guidance - StreetInsider.com
GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - MSN
GoodRx accused of conspiring with PBMs over reimbursement fees - Seeking Alpha
GoodRx Holdings Inc (GDRX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
GoodRx, PBMs Hit by Price Fixing Lawsuits - AJMC.com Managed Markets Network
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Raymond James & Associates - MarketBeat
Vanguard Group Inc's Strategic Reduction in GoodRx Holdings Inc - GuruFocus.com
GoodRx, PBMs accused of suppressing reimbursements to independent pharmacies - Reuters
GoodRx to Participate in Upcoming Investor Conferences - StockTitan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How To Trade (GDRX) - Stock Traders Daily
GoodRx Unveils New E-commerce Platform, Launches with Opill® - Quantisnow
GoodRx Unveils New E-commerce Platform, Launches with Opill® – Company Announcement - Financial Times
Assenagon Asset Management S.A. Decreases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - MarketBeat
GoodRx (GDRX) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
GoodRx (GDRX) Set to Announce Earnings on Thursday - Defense World
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon - Simply Wall St
GoodRx appoints IQVIA CFO to board for financial expertise - Investing.com India
GoodRx Holdings Strengthens Board with New Appointment - TipRanks
Ronald E. Bruehlman Joins GoodRx Board of Directors - Business Wire
GoodRx: The Tide Is Turning The Wrong Way (Rating Downgrade) (NASDAQ:GDRX) - Seeking Alpha
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus.com
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies - Marketscreener.com
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):